Performance comparison of next-generation sequencing platforms for determining HIV-1 coreceptor use

[1]  Xian-Ming Pan,et al.  HIV coreceptor tropism determination and mutational pattern identification , 2016, Scientific Reports.

[2]  J. Izopet,et al.  Position-specific automated processing of V3 env ultra-deep pyrosequencing data for predicting HIV-1 tropism , 2015, Scientific Reports.

[3]  Bie M. P. Verbist,et al.  Performance assessment of the Illumina massively parallel sequencing platform for deep sequencing analysis of viral minority variants. , 2015, Journal of virological methods.

[4]  O. Mor,et al.  Evaluation of GS Junior and MiSeq next-generation sequencing technologies as an alternative to Trugene population sequencing in the clinical HIV laboratory. , 2015, Journal of virological methods.

[5]  A. Hughes,et al.  Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq , 2014, Retrovirology.

[6]  P. Harrigan,et al.  “Deep” Sequencing Accuracy and Reproducibility Using Roche/454 Technology for Inferring Co-Receptor Usage in HIV-1 , 2014, PloS one.

[7]  David L. Robertson,et al.  Sensitive Deep-Sequencing-Based HIV-1 Genotyping Assay To Simultaneously Determine Susceptibility to Protease, Reverse Transcriptase, Integrase, and Maturation Inhibitors, as Well as HIV-1 Coreceptor Tropism , 2014, Antimicrobial Agents and Chemotherapy.

[8]  P. Massip,et al.  Genotypic Prediction of HIV-1 CRF01-AE Tropism , 2012, Journal of Clinical Microbiology.

[9]  J. Archer,et al.  Use of Four Next-Generation Sequencing Platforms to Determine HIV-1 Coreceptor Tropism , 2012, PloS one.

[10]  R. Kagan,et al.  A Genotypic Test for HIV-1 Tropism Combining Sanger Sequencing with Ultradeep Sequencing Predicts Virologic Response in Treatment-Experienced Patients , 2012, PloS one.

[11]  M. Jensen,et al.  Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  P. Massip,et al.  Frequency of CXCR4-using viruses in primary HIV-1 infections using ultra-deep pyrosequencing , 2011, AIDS.

[13]  P. Massip,et al.  Genotypic prediction of HIV-1 subtype D tropism , 2011, Retrovirology.

[14]  V. Calvez,et al.  Concordance between Two Phenotypic Assays and Ultradeep Pyrosequencing for Determining HIV-1 Tropism , 2011, Antimicrobial Agents and Chemotherapy.

[15]  Alexander Thielen,et al.  Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. , 2011, The Journal of infectious diseases.

[16]  Thomas Lengauer,et al.  Improved prediction of HIV‐1 coreceptor usage with sequence information from the second hypervariable loop of gp120. , 2010, The Journal of infectious diseases.

[17]  P. Massip,et al.  Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[18]  John Archer,et al.  Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing , 2009, AIDS.

[19]  Anders Karlsson,et al.  Maraviroc for previously treated patients with R5 HIV-1 infection. , 2008, The New England journal of medicine.

[20]  L. Cuzin,et al.  Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism , 2008, AIDS.

[21]  Natalia Chueca,et al.  Evaluation of Eight Different Bioinformatics Tools To Predict Viral Tropism in Different Human Immunodeficiency Virus Type 1 Subtypes , 2008, Journal of Clinical Microbiology.

[22]  Thomas Lengauer,et al.  Bioinformatics prediction of HIV coreceptor usage , 2007, Nature Biotechnology.

[23]  M. Ronaghi,et al.  Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. , 2007, Genome research.

[24]  Christophe Pasquier,et al.  Population-Based Sequencing of the V3 Region of env for Predicting the Coreceptor Usage of Human Immunodeficiency Virus Type 1 Quasispecies , 2007, Journal of Clinical Microbiology.

[25]  Tobias Sing,et al.  Determining Human Immunodeficiency Virus Coreceptor Use in a Clinical Setting: Degree of Correlation between Two Phenotypic Assays and a Bioinformatic Model , 2006, Journal of Clinical Microbiology.

[26]  H. Schuitemaker,et al.  Relation of phenotype evolution of HIV-1 to envelope V2 configuration. , 1993, Science.

[27]  H. Schuitemaker,et al.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population , 1992, Journal of virology.

[28]  J. Farber,et al.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.